title: The feasibility of a novel bioreactor for vaccine production of classical swine fever virus.
abstract: The performance of a new type of tide mode culture system was investigated in this study. This novel bioreactor provides two separated stages, liquid and gas, for cell growth requirements. The immobilized cells absorbed the nutrient from medium during the liquid stage and subsequently were exposed directly to fresh air to absorb oxygen during the gas stage. Operating with PK15 cells under optimal conditions, we obtained 2.3×10(9) cells in 500ml reactor. It is 30 times higher than the initial inoculum and about 11 times higher than the production by roller bottle. For the vaccine production of classical swine fever (CSFV), a high virus titer of 2.1×10(9) median tissue culture infective dose (TCID(50)) was yielded which provided exceed 300 doses per milliliter of CSFV solution. Therefore, this new cultural system performed well not only for cell production but also for virus yield. It should be a highly efficient production for the CSFV vaccine and have practical potential in other animal cell culture vaccine.
authors.affiliation: Department of Biotechnology, Fooyin University, Kaohsiung City, Taiwan, ROC. dr009@mail.fy.edu.tw
authors.forename: Sheng-Chi
authors.initials: SC
authors.lastname: Wu
authors.forename: Ming-Yi
authors.initials: MY
authors.lastname: Liau
authors.forename: Ya-Ching
authors.initials: YC
authors.lastname: Lin
authors.forename: Chong-Jun
authors.initials: CJ
authors.lastname: Sun
authors.forename: Chi-Ting
authors.initials: CT
authors.lastname: Wang
mesh_terms: D000818:Animals; D019149:Bioreactors; D001709:Biotechnology / Q000379:methods*; D002460:Cell Line; D018914:Cells, Immobilized; D006692:Classical Swine Fever Virus / Q000254:growth & development*; D003470:Culture Media / Q000737:chemistry; D013552:Swine; D013678:Technology, Pharmaceutical / Q000379:methods*; D019562:Viral Load; D014765:Viral Vaccines / Q000302:isolation & purification*
chemical_list: D003470:Culture Media; D014765:Viral Vaccines